Urinary release of 72 and 92 kDa gelatinases, TIMPs, N-GAL and conventional prognostic factors in urothelial carcinomas

European Urology

Volumn 42, Issue 4, 2002, Pages 356-363

  Monier, Frederique ^a   Mollier, Serge ^b   Guillot, Michele ^a   Rambeaud, Jean Jacques ^b   Morel, Francoise ^a   Zaoui, Philippe ^a  

^a Laboratoire d'Enzymologie   (France)

^b Department of Urology and Renal Transplantation Surgery   (France)

Author keywords

ELISA; Gelatinases; N GAL; TIMPs; Urothelial carcinoma; Zymography

Indexed keywords

GELATINASE A; GELATINASE B; LIPOCALIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CELL MOTILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; FOLLOW UP; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSITIONAL CELL CARCINOMA; UROGENITAL TRACT TUMOR; ZYMOGRAPHY; AGE; BLADDER TUMOR; FRANCE; MIDDLE AGED; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEX DIFFERENCE; URINE; UROTHELIUM;

ADULT; AGE FACTORS; AGED; CARCINOMA, TRANSITIONAL CELL; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; FRANCE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; PROGNOSIS; SEX FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0036795252     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00350-0     Document Type: Article

References (19)

1. Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455-63.
2. Shapiro SD. Matrix metallloproteinase degradation of extra cellular matrix: biological consequences. Curr Op Cell Biol 1998;10:602-8.
3. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of N-GAL. a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32.
4. Hermanek P, Sobin L. International Union Against Cancer: TNM Classification of Malignant Tumors. 4th ed. Berlin: Springer, 1987.
5. Mostofi F, Sobin L, Torloni H. Histological Typing of Urinary Bladder Tumors. Geneva: World Health Organization, 1973.
6. Laemmli UK, Favre M. Maturation of the head bacteriophage T4: DNA packaging events. J Mol Biol 1973;80:575-99.
7. Woessner JF. Quantification of MMPs in tissue samples. Methods Enzymol 1995;248:510-28.
8. Morel F, Berthier S, Guillot M, Zaoui P, Massoubre C, Didier F, Vignais PV. Human neutrophil gelatinase is a collagenase type IV. Biochem Biophys Res Commun 1993;191:269-74.
9. Towbin UK, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350-4.
10. Kolkenbrock H, Hecker-Kia A, Orgel D, Kinawi A, Ulbrich N. Progelatinase B forms from human neutrophils: complex formation of monomer/lipocalin with TIMP-1. J Biol Chem 1996;377:529-33.
11. Kawamata H, Kameyama S, Kawai K, Tanaka Y, Nan L, Barch DH, et al. Marked acceleration of the metastatic phenotype of a rat bladder carcinoma cell line by the expression of human gelatinase A. Int J Cancer 1995;63:568-75.
12. Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer 1998;82:1359-66.
13. Furukawa A, Tsuji M, Nishitani M, Kanda K, Inoue Y, Kanayama H, et al. Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase families in noninvasive and invasive tumors transplanted in mice with severe combined immunodeficiency. Urology 1998;51:849-53.
14. Margulies IM, Hoyhtya M, Evans C, Stracke ML, Liotta LA, Stetler-Stevenson WG. Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev 1992;1:467-74.
15. Ozdemir E, Kakehi Y, Okuno H, Yoshida O. Role of matrix metalloproteinase-9 in the basement membrane destruction of superficial urothelial carcinomas. J Urol 1999;161:1359-63.
16. Bianco FJ, Gervasi DC, Tiguert R, Grignon DJ, Pontes JE, Crissman JD, et al. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 1998;4:3011-6.
17. Gohji K, Fujimoto N, Komiyama T, Fujii A, Ohkawa J, Kamidono S, Nakajima M. Elevation of serum levels of matrix metalloproteinase-2 and -3 as new predictors of recurrence in patients with urothelial carcinoma. Cancer 1996;78:2379-87.
18. Kitawaga Y, Kunimi K, Ito H, Sato H, Uchibayashi T, Okada Y, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human urothelial carcinomas. J Urol 1998;160:1540-5.
19. Hampton AL, Nie G, Salamonsen LA. Progesterone analogues similarly modulate endometrial matrix metalloproteinase-1 and matrix metalloproteinase-3 and their inhibitor in a model for long-term contraceptive effects. Mol Hum Reprod 1999;5:365-71.